Home › Burkitt Lymphoma › Illinois
Burkitt Lymphoma clinical trials in Illinois
14 studies for Burkitt Lymphoma are looking for participants at sites in Illinois.
Cities in Illinois
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 4 more
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 2, 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- and 7 more
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Oct 2, 2026 · NCT03150693Blinatumomab Consolidation in Real World
- Northwestern University, Chicago
- The University of Chicago, Chicago
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07117136Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 9 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- and 3 more
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 2 more
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 5 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Chicago
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Chicago
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Jul 13, 2026 · NCT07109219Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 2
Ages 18 to 54 · All sexes · Updated Mar 17, 2026 · NCT06918431ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- University of Chicago, Chicago
RecruitingPhase 1/2
Ages 15 to 50 · All sexes · Updated Sep 9, 2025 · NCT04150497Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Recruiting
Ages 18 to 50 · All sexes · Updated Jun 19, 2025 · NCT06785324From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.